FDA Fast Track Designation for LOAd703 for the treatment of Pancreatic Cancer
This is an important milestone for Lokon Pharma, said Dr. Angelica Loskog (CEO/CSO). She continues, “Pancreatic cancer is a remaining challenge within immune oncology. Lokon’s LOAd703 gene engineers the TME to express strong immune activators and thereby induces an inflammation that can sensitize these patients to traditional immunotherapy with checkpoint blockade antibodies. LOAd703 is currently evaluated in combination with gemcitabine and nab-paclitaxel plus an anti-PD-L1 antibody in pancreatic cancer and a randomized phase II study is on the way.”
Share:
More News
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of
“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data